# Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

> **NCT00723125** · PHASE2 · COMPLETED · sponsor: **William Sikov MD** · enrollment: 60 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Carboplatin
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT00723125
- **Lead sponsor:** William Sikov MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2014-05-15
- **Final completion:** 2014-05-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723125, "Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00723125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*